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Abstract
Objective: The study evaluated the efficacy of phototherapy and 20% albumin infusion to reduce total serum bilirubin (TSB) in neonates with severe hyperbilirubinemia. The primary outcome was a reduction of TSB at the end of treatment. The secondary outcomes were the need for exchange transfusion, inpatient mortality, neurological outcomes
at discharge, and development outcomes at 12-months follow-up.
Results: One hundred and eighteen neonates were randomly assigned to phototherapy and 20% albumin (n = 59)
and phototherapy and saline (n = 69). The median age at admission was 5 (interquartile range (IQR) 3–6) days, and the
median gestation was 36 (IQR 36–38) weeks. No significant differences were found in the change in TSB (Mann–Whitney U =609, p = 0.98) and rate of change in TSB per hour after treatment (Mann–Whitney U = 540, p = 0.39) between
the two groups. There were no significant differences between the two groups in the proportion of participants who
required exchange transfusion (χ2 (2) = 0.36, p = 0.546); repeat phototherapy (χ2 (2) = 2.37, p = 0.123); and those who
died (χ2 (2) = 0.92, p = 0.337). Trial registration The trial was registered in the International Standardized Randomized
Controlled Trial Number (ISRCTN); trial registration number ISRCTN89732754.
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Introduction
Neonatal jaundice (NNJ) is a common condition [1]
and occurs when the breakdown of red blood cells is
increased leading to an accumulation of bilirubin [2].
Globally, the overall incidence of NNJ is 9.9 (2.8–35.6)
per 10,000 live births [1]. Africa has the highest number of children developing NNJ with an incidence of
667.8 (603.4–738.5) per 10,000 live births [1]. In Kilifi
County Hospital (KCH) Kenya, NNJ accounted for 24%
of young infants’ mortality and was the primary diagnosis of 17% of over 1000 neonatal admissions during the
first 60 days of life in 2003 [3]. Neonates may develop
hyperbilirubinemia; total serum bilirubin (TSB) above
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the 95th percentile for that age (in hours). Phototherapy
is the treatment of choice as it enhances the conversion
of bilirubin into less toxic water-soluble photo-isomers
[4] and is effective in the management of NNJ [5–9].
Severe unconjugated hyperbilirubinemia can cause neurotoxicity that leads to brain damage in neonates [10] and
is associated with irreversible neurodevelopmental, and
neurological impairment [11–16].
The use of blue-light fluorescent tubes during phototherapy increases the need for maintenance fluid by 25%
and additional intravenous fluid 1–1.5 times the maintenance fluid during intensive phototherapy [17]. The
increased fluid, mainly dextrose water is needed to compensate for fluid lost in the excretion of the water-soluble
photo-products from bilirubin conversion. Lack of fluid
may lead to dehydration in children undergoing phototherapy [18]. Moreover, adequate hydration and urine
output improve the efficacy of phototherapy.
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Albumin infusion during phototherapy is reported to
induce a rapid decline in unconjugated bilirubin during phototherapy [19] since albumin binds to bilirubin.
Hosono et al. reported that 25% albumin infusion was
more effective in reducing serum levels of unbound bilirubin during the first 6 and 24 h of treatment compared
to phototherapy alone [20], but did not significantly
reduce TSB levels at the end of treatment. In another
study, it was reported that 10% albumin had a protective
effect against bilirubin toxicity and may be useful in children with severe hyperbilirubinemia [21]. Hosono et al.
further report that albumin infusion therapy is associated
with better hearing outcomes at 6 months compared to
standard care [22].
Despite the knowledge that albumin infusion during
phototherapy may be useful, most of the evidence is from
high-income countries, and less is known in sub-Saharan
Africa (SSA) despite the high incidence of NNJ. The present study evaluated the efficacy of phototherapy and
20% albumin infusion versus standard care (phototherapy and saline) in the reduction of bilirubin, exchange
transfusion, inpatient mortality, neurological outcomes
at discharge and development outcomes at 12-months.

Main text
Methods
Trial design

This is a randomized controlled trial of phototherapy
and 20% albumin versus phototherapy and saline. The
enrolled participants were randomized in a ratio of 1:1 to
the albumin group and saline group.
Participants

The study was conducted at KCH from 2006 to 2011. All
neonates admitted to KCH had a clinical assessment of
NNJ. TSB was measured in neonates (0–30 days) admitted to the KCH paediatric ward on the day of admission.
Those with a TSB above 250 μmol/L were investigated
to determine the cause of hyperbilirubinemia and were
randomized to either phototherapy and 20% albumin
or phototherapy and saline. The decision to start phototherapy was calculated based on the postnatal age, gestational, and TSB levels at admission [23]. Phototherapy
was initiated when TSB levels were from 85µ/mols/L/kg
in babies below 2.5 kg (as a marker of prematurity). For
sick neonates, treatment was started at 30µ/mols/L below
the levels for the well baby. Participants were excluded
from the study if they had a congenital abnormality, clinical evidence of kernicterus, or obstructive jaundice.
Interventions

Neonates randomized to receive albumin were given one
infusion of intravenous 20% albumin (1 g/kg) over 2 h.
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The neonates that were randomized to 1/5 (0.9%) normal
saline sodium 154 mmol/L and chloride 154 mmol/L in
10% dextrose received the same volume of fluid as those
randomized to 20% albumin i.e. 5 ml/kg over a period of
2 h. Hyperbilirubinemia was managed using Photolight,
Model AS20 220–230 V with YZ20BT132/20W blue fluorescent tubes. All children were on a routine antibiotic
cover (Benzyl Penicillin and Gentamicin) and maintenance fluids (10% dextrose) [23]. Discharge from the hospital occured only when the TSB was below phototherapy
level (less than 85/μmol/l/kg) and after 24 h observation
to check for rebound hyperbilirubinemia after phototherapy was stopped.
Blood samples were taken for laboratory tests such as
blood group determination and Coombs test (direct and
indirect). Haemolytic causes were defined as motherbaby blood incompatibility or Coombs test positive. TSB
was measured at admission, at 2 h, 6 h, 24 h, 48 h post
admission, and every 24 h thereafter until the child was
discharged. Participants were withdrawn from phototherapy if there was a need for exchange transfusion, hospital transfer, or death.
Study Outcomes

The primary study outcome was the reduction in TSB
levels for the participants at the end of treatment. The
secondary outcomes were the prevention of exchange
transfusions during treatment, reduced inpatient mortality, neurological outcomes at discharge and developmental outcomes at 12-months.
Neurological and developmental assessment

A neurological assessments were performed using a
clinical evaluation proforma designed for this study and
assessed at discharge by a clinician blinded to the participants’ treatment arm. The developmental assessments
were taken at 12-months of age by trained assessors.
The Kilifi Development Inventory (KDI) [24, 25] and the
Developmental Milestones Checklist (DMC) [24, 25]
were administered to evaluate psychomotor, language
and social emotional function.
Sample size

The sample size was based on previous data from KCH in
which 48% of children with severe hyperbilirubinaemia
had neurological deficits [11]. To detect a 50% difference
in neurological sequelae in the albumin-treated group,
assuming 80% power, 70 participants in both arms were
required giving a total of 140 participants. Adjustment
for death and loss to follow up of 10% required 80 participants in each arm giving a total of 160 participants.
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Enrolment and randomization

The randomization was undertaken using card envelopes
in blocks of 20. The random numbers were generated
by the principal investigator and kept in serially numbered sealed opaque envelopes which were only opened
after participants were enrolled in the study. However,
due to the nature of this study, it was not possible for
the investigators, assessors, clinicians, and parents to be
blinded to the treatment arm once the participants were
randomized.
Statistical analysis

Data were recorded on files, and double entered to a
secure, Web-based REDCap database and analysed using
STATA (version 15) [26]. Descriptive statistics such as
frequencies, percentages, and median with respective
interquartile ranges (IQR) were reported. Wilcoxon test
was used to compare differences in TSB at admission and
after treatment, while Mann–Whitney U test was used to
compare the differences in change in TSB (the difference
in TSB levels at the start and end of treatment) and rate of
change per hour in TSB (the difference in the level of TSB
at admission and at the end of treatment divided by the
total number of hours taken on phototherapy) between
the two treatments. Chi square test was used for comparisons of the proportion of participants who required
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exchange transfusion, repeat phototherapy, died, and
participants who were discharged in the two treatments.
Results

One hundred and fifty-six participants were randomized
in the study (75 assigned to 20% albumin while 76
assigned to saline).
Demographic characteristics and proportion of participants who required exchange transfusion were analysed
on 118 participants (59 in the 20% albumin arm and 69 in
the saline arm).
Reduction in TSB levels in the two treatments was
assessed on the 70 participants (34 in 20% albumin arm
and 36 in the saline arm) whose data were available (see
Additional file 1: Figure S1).
Participant characteristics

The baseline characteristics of participants enrolled in
the study are given in Table 1. There were no significant
differences in the demographic and baseline characteristics between the participants who received phototherapy
and albumin and phototherapy and saline at baseline.
The median age at admission was 5 (IQR 3–6) days, the
median gestation was 36 (IQR 36–38) weeks, and the
median age for the mothers was 24 (IQR 19–28) years.
Most of the participants (40.8%) had haemolytic causes
of jaundice, 14.6% had non-haemolytic causes, 15.4%

Table 1 Baseline characteristics participants
Characteristics

20% albumin + phototherapy (n = 59)

Saline + phototherapy (n = 69)

Test statistic

5 (3–6)

5 (4–6)

P =0.574*

36 (36–37)

36 (36–38)

–

368 (303–456)

392 (316–510)

P =0.331*

24 (19–29)

24 (20–27)

P =0.331*

Yes

28

25

No

18

28

χ2(2) = 1.85, P =0.173

Yes

10

9

No

36

41

Age at admission (days)
Median (IQR)
Estimated gestational weeks
Median (IQR)
Total serum bilirubin at admission
Median (IQR)
Mother’s age
Median (IQR)
ABO incompatibility n

Non-haemolytic causes n
χ2(2) = 0.21, P =0.646

Both haemolytic and non-haemolytic n
Yes

5

3

No

54

66

Yes

13

18

No

46

51

χ2(2) = 0.92, P =0.336

Unknown causes

* Mann U Whitney

χ2(2) = 0.28, P =0.594
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had both haemolytic and non-haemolytic causes, while
in 29.2% of the participants the causes of jaundice were
unknown.
Reduction in bilirubin levels after treatment

The participants’ TSB levels after treatment were significantly lower than TSB levels at admission in both the
phototherapy and albumin (Z = 5.1, p < 0.00) and phototherapy and saline (Z = 5.2, p < 0.001) groups. There were
no significant differences in the change in TSB (Mann–
Whitney U =609, p = 0.98) and rate of change in TSB per
hour (Mann–Whitney U = 540, p = 0.39) between the
two groups (Table 2).
Outcome after treatment

There were no significant differences (p > 0.05) in the
proportion of participants who required exchange transfusion (three in albumin group versus four in saline
group), repeat phototherapy (two in albumin versus none
in saline), those who died (six in albumin group versus
eleven in saline group), and participants who were discharged in the two treatments (Table 3).

neurological impairment at discharge and improve developmental outcome at 12-months. The results reveal that
albumin infusion lowers the TSB levels during treatment, but there were no significant changes in TSB levels
and rate of change in TSB per hour between the albumin infusion arm and the control group. Additionally,
no significant differences were found in other outcomes
including the need for repeat phototherapy, exchange
transfusion, inpatient mortality, and developmental outcomes at 12-months.
One of the reasons for the lack of effect of albumin
infusion during phototherapy could be that the extraction of bilirubin from the tissues and its discharge into
the blood depend on the phototherapy rather than
additional albumin infused. These findings are similar
to those reported by Hosono et al. and Tsao and Victor who reported no significant reduction in TSB levels
between the 25% albumin infusion group and control
group. The second reason for lack of additional effect of
albumin infusion during phototherapy is that albumin
may lead to an increase in oncotic pressure, expanding
plasma volume hence delay the excretion of bilirubin

Developmental outcomes at age 12‑months

There was no significant difference in the 20% album
group and saline group in the scores for psychomotor (M = 26.5, SD = 11.5, versus M = 20.1, SD = 13.8),
t (55) = 1.9, p = 0.060; language (M = 7.3, SD = 4.3 versus M = 5.4, SD = 4.2), t (55) = 1.7, p = 0.090 and socioemotional function (M = 26.5, SD = 11.5 versus M = 25.7,
SD = 11.8), t (55) = 0.9, p = 0.360.
Discussion

This randomized control trial investigated the efficacy
of 20% albumin infusion in neonates with severe hyperbilirubinemia to enhance the binding of bilirubin in
the plasma and consequently reduce TSB, the need for
exchange transfusion, mortality during phototherapy,

Table 3 Outcome after treatment
20% albumin Saline (n = 69)
(n = 59)

Test statistic

Type of discharge n (%)
Alive

53 (89.8)

58 (84.1)

Died

6 (10.2)

11 (15.9)

χ2 (2) = 0.920,
P = 0.337

Repeat phototherapy n (%)
Yes

2 (3.4)

0 (0.0)

No

57 (96.6)

69 (100.0)

χ2 (2) = 2.376,
P = 0.123

Exchange transfusion n (%)
Yes

3 (4.4)

4 (6.8)

No

55 (95.6)

66 (93.2)

Abnormal neuro–
logical functioning

χ2 (2) = 0.364,
P = 0.546

–

Table 2 Reduction in bilirubin levels at end of treatment in whom complete data were available
Variable

20% albumin + phototherapy (n = 34)

Saline + phototherapy
(n = 36)

TSB at admission mean (SD)

387 (114)

370 (102)

TSB after phototherapy mean (SD)

191 (67)

188 (69)

152 (101–248)

159 (101–230)

2.16 (1.5–4.25)

1.91 (1.19–4.00)

Change in bilirubin*
Median (IQR)
Rate of change (mg/dL/h)*
Median (IQR)
Descriptive statistics
SD standard deviation
* No significant differences in change of total serum bilirubin and rate of change in total serum reduction per hour between the two arms of the trial p > 0.05
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from the body [20]. Third, the apparent ineffectiveness
of albumin infusion may be due to oxidation of albumin
during phototherapy. Oxidized albumin has a lesser
affinity for bilirubin than albumin, thus promotes accumulation of free bilirubin in the body [19].
In a recent Cochrane meta-analysis evaluating the role
of fluid supplementation in the treatment of NNJ, the
authors reported that there were no differences between
the treatment and control groups in the TSB levels 4 h
after phototherapy [27]. However, several studies have
reported the effectiveness of albumin infusion during
exchange transfusion [21, 28, 29]. These studies have
indicated that the effect of albumin infusion is useful
in the clearance of bilirubin from the neonates’ tissues
which may not be cleared by exchange transfusion.

Limitations
There were a number of limitations to this trial. First, the
trial was not a double-blind trial, although, the endpoints
of bilirubin and the need for exchange transfusions are
unlikely to be biased outcomes. Second, the plasma concentrations of unbound bilirubin were not consistently
measured for participants in the treatment and control
group, therefore, it is difficult to determine whether the
infusion of albumin affected the unbound bilirubin or
not. Additionally, the developmental assessments may
not have detected more subtle impairments at 12 months
of age that could impact functional abilities at a later age.
Finally, the study had missing data on some participants
hence they could not be included in this analysis. The
missing data may potentially reduce the representativeness of the sample and introduced biasness in the estimations of the outcomes of this study.
Supplementary information
Supplementary information accompanies this paper at https://doi.
org/10.1186/s13104-019-4632-2.
Additional file 1: Figure S1. Enrolment, randomization, treatment, and
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through the different phases of the parallel randomised control trial. The
information provided accounts for the participants enrolled, randomized,
treated, and evaluated in the study.
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